Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer
Author:
Affiliation:
1. Department of Oncology; Asan Medical Center; University of Ulsan College of Medicine; Seoul Korea
2. Department of Internal Medicine; Medical Oncology and Hematology; Pusan National University Yangsan Hospital; Korea
Publisher
Wiley
Subject
Oncology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12592/fullpdf
Reference18 articles.
1. Biliary tract cancers;Groen;N Engl J Med,1999
2. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update;Khan;Gut,2012
3. Indication of hepatopancreatoduodenectomy for biliary tract cancer;Hirono;World J Surg,2006
4. Patterns of initial disease recurrence after resection of biliary tract cancer;Jung;Oncology,2012
5. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study;Valle;Br J Cancer,2009
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling;Drug Discoveries & Therapeutics;2023-10-31
2. Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population;Biomedicines;2023-10-30
3. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer;Targeted Oncology;2023-09-26
4. Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome;Diagnostics;2023-05-23
5. Comparison of laparoscopic and open pancreaticoduodenectomy for the treatment of distal cholangiocarcinoma: A propensity score matching analysis;Frontiers in Oncology;2022-11-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3